News
Perceptive Bioscience Investments announces launch of company
Media release: Perceptive Bioscience Investments Ltd.
London: February 22 2016. Perceptive Bioscience Investments Ltd, a new global health and life sciences company investing in medical innovation, has commenced operations with initial funding from institutional investors.
Headquartered in London and with offices in New York, Perceptive Bioscience Investments has developed a broad investment strategy providing seed, venture and growth capital as well as private and public equity.
The company has commenced operations with funding led by Woodford Investment Management and other institutional investors. Perceptive’s evergreen structure permits further capital raising, which will continue as investment opportunities arise. The company has access to an extensive pipeline of deals and current market conditions are creating increasingly attractive valuation entry points.
Perceptive Bioscience Investments has been formed by leading figures in the international health and life science investment community; Dr Joe Anderson, Chief Executive Officer (formerly a partner with Abingworth LLP), Jonathan Peacock, Chairman (formerly CFO of Amgen and Novartis Pharma) and Professor Sir Christopher Evans, OBE, Deputy Chairman (one of Europe’s most successful entrepreneurs).
Due to Perceptive’s structure and the extensive expertise and industry networks of its management and investment team, the company offers investors access to breakthrough science and high potential life sciences investment opportunities worldwide. The company has already secured relationships with science-based universities in the UK, EU and Australia as well as in the US through an established network of leading academic centres and companies.
Jonathan Peacock, Chairman of Perceptive Bioscience Investments, said: “Our mission is to finance and support the development of medical innovations led by a senior team with depth and broad experience as entrepreneurs, investors and operators in this space. Joe, Chris and I will be supported by a broad team of investment professionals in Europe and the US. These capabilities plus the range of projects under consideration have been very attractive to investors seeking exposure to a portfolio of emerging and innovative biotech companies under active and experienced ownership.”
Dr Joe Anderson, CEO of Perceptive Bioscience Investments, said: “The creation of the company is an exciting development in biomedical science and we are fortunate to have the support of leading investors as we build a truly flexible investment platform. Outstanding investment opportunities are to be found from start-ups in universities to mispriced public companies with products in late-stage development. Profound advances are underway in medical innovation and we are keen to help companies speed their development with finance and practical support, whatever their stage of development.”
Professor Sir Chris Evans, deputy chairman, commented: “There was a real need and appetite for an exceptionally dynamic investment company that has a wealth of scientific, commercial and financial experience, and which can operate at the highest level and be at the heart of health and life sciences investment around the world. That is why we have created Perceptive.”
Key Investment highlights:
A new health and life sciences specialist based in Europe and the US with global reach, seeking to:
Unlock value in private and public companies with patient capital and practical support.
Support competitive early stage companies with privileged access to breakthrough academic science.
Evergreen structure with the capability to finance medical innovation through all stages of its development. Perceptive provides seed capital, venture capital, growth capital, private equity and public equity.
Perceptive is committed to making investments from its own balance sheet.
Broad reach. Access to the best scientific ideas not limited to any one university or country.
Academic relationships. Exclusive and privileged relationships already in place with universities in the UK, EU, Australia and the US.
Extensive industry networks with rich sources of deal flow.